Literature DB >> 27501402

A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid.

Taku Fujimura1, Aya Kakizaki1, Sadanori Furudate1, Setsuya Aiba1.   

Abstract

Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are autoimmune blistering diseases, and substantial numbers of CD163+ tissue-associated macrophages (TAMs) are detected in both diseases. PV and BP possess different subsets of helper T cells, suggesting that the cytokine profiles of PV and BP might be different. The purpose of this study was to investigate the microenvironment of lesional skin and serum of PV and BP patients, focusing on the immunomodulatory factors related to TAMs, such as periostin (POSTN), chemokines, cytokines and matrix metalloproteinases (MMPs). We first performed immunohistological staining of POSTN in PV and BP lesions. POSTN was prominent in the superficial dermis in both PV and BP lesions. Next, to validate the activation of CD163+ TAMs in PV and BP patients, we examined the serum levels of soluble (s)CD163. The serum sCD163 levels in PV and BP patients are significantly higher than in healthy controls. To further elucidate the molecular mechanisms of the effects of POSTN on CD163+ TAMs in PV and BP, we examined chemokines, MMPs and cytokines selected by DNA microarray database. The serum CXCL5 levels from PV patients are significantly higher than those in BP patients and healthy controls. The IL-36γ expression on infiltrating macrophages was prominent only in the lesional skin of PV, while the MMP12 deposition was detected in both PV and BP lesions. Our results shed light on the novel pathogenesis of PV through CD163+ TAMs.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CXCL5; IL-36; pemphigus; periostin; tissue-associated macrophages

Mesh:

Substances:

Year:  2017        PMID: 27501402     DOI: 10.1111/exd.13157

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

Review 1.  Periostin in the pathogenesis of skin diseases.

Authors:  Hiroyuki Murota; Yang Lingli; Ichiro Katayama
Journal:  Cell Mol Life Sci       Date:  2017-09-15       Impact factor: 9.261

2.  Low periostin expression predicts poor survival in intestinal type gastric cancer patients.

Authors:  Teming Zhang; Zheng Han; Arvine Chandoo; Xincheng Huang; Xiangwei Sun; Lele Ye; Changyuan Hu; Xiangyang Xue; Yingpeng Huang; Xian Shen; Wenjun Chang; Xiaoming Lin
Journal:  Cancer Manag Res       Date:  2018-12-18       Impact factor: 3.989

Review 3.  Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.

Authors:  Yoshiyuki Nakamura
Journal:  Front Med (Lausanne)       Date:  2019-05-29

Review 4.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 5.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Authors:  Rossana Franzin; Giuseppe Stefano Netti; Federica Spadaccino; Camillo Porta; Loreto Gesualdo; Giovanni Stallone; Giuseppe Castellano; Elena Ranieri
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 6.  Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.

Authors:  Taku Fujimura; Yumi Kambayashi; Yasuhiro Fujisawa; Takanori Hidaka; Setsuya Aiba
Journal:  Front Oncol       Date:  2018-01-23       Impact factor: 6.244

7.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13

8.  Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

Authors:  Kayo Tanita; Taku Fujimura; Yumi Kambayashi; Akira Tsukada; Yota Sato; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-02-15

9.  Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Authors:  Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Sadanori Furudate; Takanori Hidaka; Setsuya Aiba
Journal:  Oncotarget       Date:  2018-02-15

Review 10.  Cancer-Associated Fibroblasts: Understanding Their Heterogeneity.

Authors:  Kévin Louault; Rong-Rong Li; Yves A DeClerck
Journal:  Cancers (Basel)       Date:  2020-10-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.